Business Practice

Angus Dalgleish tells us about his experience with EU regulation – and why he thinks Britain should leave the EU.

As politicians and the public argue over the minor point of the UK leaving Europe, we ask a more important question: what will a “Brexit” mean for the global pharmaceutical industry?

Intellectual property issues have suffocated many industry collaborations. And though IP is clearly valuable to pharma companies, there is also value in learning to let go.

A US coalition seeks lower prices for US prescription drugs, but could their proposals undermine the competitive market?

Abbott, Abbvie and Sanofi all make separate merger announcements – on the same day

What’s the best way to present a health resource? Apparently, ease of use trumps all other factors

Are you a budding biotech or pharma startup? “The Hive” could be your chance to showcase your work

Sitting Down With... Ann Hayes, Owner, The Ann Hayes Consultancy, Stevenage, UK.

Welcome to The Power List 2016

Innovation is increasingly coming from small biotechs, but such companies rely on external funding to develop the compounds. A solid regulatory strategy is essential to convince investors to fund the further development.